Vertex reported Phase 3 data showing its acquired therapy cut a key biomarker for IgA nephropathy by roughly 50%, mirroring or exceeding results from peers and positioning the program as a potential blockbuster. The company said the result matches data from Otsuka’s Voyxact and compared favorably with Vera Therapeutics’ numbers. Vertex acquired the asset as part of a multi‑billion dollar deal and now sees best‑in‑class potential in a disease population it estimates at ~330,000 patients in the U.S. and Europe. The company’s shares rose in after‑hours trading on the news. Analysts note that positive Phase 3 biomarker outcomes could accelerate regulatory discussions and commercial planning in a crowded but lucrative renal disease market.